Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MiMe-A: Abemaciclib in Platinum-Refractory Cancers
NCT03339843Phase 2Completed
- Sponsor
- Institut Jules Bordet
- Start
- Dec 2018
- Primary completion
- Nov 2021
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of abemaciclib in esophageal adenocarcinoma (EAC), Esophageal Squamous Cell Carcinoma (ESCC), cholangiocarcinoma (CCA), urothelial carcinoma (UC), endometrial cancer (EC), sponsored by Institut Jules Bordet. Started Dec 2018; status: completed.
02
Drugs
abemaciclib
03
Conditions
esophageal adenocarcinoma (EAC)Esophageal Squamous Cell Carcinoma (ESCC)cholangiocarcinoma (CCA)urothelial carcinoma (UC)endometrial cancer (EC)
Beyond the preview
Go deeper on NCT03339843.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03339843.